Get the Stockscreener App
20.92
3.36%
0.681
Pacira Biosciences Inc stock is traded at $20.92, with a volume of 374.63K.
It is up +3.36% in the last 24 hours and down -19.60% over the past month.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
See More
Previous Close:
$20.24
Open:
$20.15
24h Volume:
374.63K
Relative Volume:
0.44
Market Cap:
$860.22M
Revenue:
$681.75M
Net Income/Loss:
$70.47M
P/E Ratio:
14.43
EPS:
1.45
Net Cash Flow:
$173.19M
1W Performance:
+1.31%
1M Performance:
-19.60%
6M Performance:
-6.73%
1Y Performance:
-6.82%
1-Day Range:
$20.15
$21.12
1-Week Range:
$18.80
$21.12
52-Week Range:
$18.80
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
Name
Pacira Biosciences Inc
Sector
Phone
650-242-8052
Address
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
20.93 | 831.86M | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
123.97 | 55.12B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.97 | 50.80B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.27 | 45.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.64 | 36.04B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
470.64 | 20.23B | 3.08B | 1.24B | 1.07B | 25.61 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Equal Weight |
| Nov-17-25 | Initiated | H.C. Wainwright | Buy |
| Jul-25-25 | Upgrade | Truist | Hold → Buy |
| Jan-30-25 | Upgrade | Truist | Sell → Hold |
| Aug-13-24 | Downgrade | Truist | Buy → Sell |
| Aug-12-24 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-12-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-12-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-03-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-07-24 | Resumed | JP Morgan | Overweight |
| Dec-20-23 | Initiated | Raymond James | Outperform |
| Aug-03-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Jan-31-23 | Resumed | Wedbush | Outperform |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jan-03-22 | Resumed | JP Morgan | Overweight |
| Jul-26-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-21-21 | Resumed | JP Morgan | Neutral |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-11-21 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jan-21-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-06-20 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Apr-07-20 | Initiated | Northland Capital | Outperform |
| Mar-20-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Nov-06-19 | Initiated | BTIG Research | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-06-19 | Upgrade | Mizuho | Underperform → Neutral |
| May-02-19 | Upgrade | Stifel | Sell → Hold |
| Feb-01-19 | Downgrade | Mizuho | Neutral → Underperform |
| Aug-06-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Apr-09-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-21-18 | Reiterated | Mizuho | Neutral |
| Feb-16-18 | Downgrade | Needham | Buy → Hold |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Jan-04-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Mkt Perform |
View All
Pacira Biosciences Inc Stock (PCRX) Latest News
Pacira partners with LG Chem to make EXPAREL® available in select APAC markets - BioSpectrum Asia
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
DOMA Perpetual Capital to offer nominees for Pacira BioSciences board - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Reach Out - ACCESS Newswire
Revenues Working Against Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Share Price Following 28% Dive - simplywall.st
Benign Growth For Pacira BioSciences, Inc. (NASDAQ:PCRX) Underpins Stock's 28% Plummet - 富途资讯
Pacira BioSciences Inc (PCRX) Stock Price Down 5.4% on Jan 16 - GuruFocus
Market Outlook: Is Great Elm Group Inc subject to activist investor interestPortfolio Performance Summary & Smart Swing Trading Alerts - baoquankhu1.vn
Pacira BioSciences (NASDAQ:PCRX) Hits New 52-Week LowTime to Sell? - MarketBeat
Do Options Traders Know Something About Pacira BioSciences Stock We Don't? - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Connect - ACCESS Newswire
Pacira BioSciences (NASDAQ:PCRX) Shares Down 6.9%What's Next? - MarketBeat
Pacira drops after adjusting 2025 revenue below consensus - MSN
PCRX, LG Chem Partner to Expand Exparel Reach Across the Asia-Pacific - Finviz
Pacira BioSciences Signs Deal With LG Chem To Commercialize EXPAREL In Select Asia-Pacific Markets - Nasdaq
LG Chem to distribute Pacira’s EXPAREL in Asian-Pacific markets By Investing.com - Investing.com India
LG Chem to distribute Pacira’s EXPAREL in Asian-Pacific markets - Investing.com
Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets - The Manila Times
Opioid-sparing EXPAREL to reach patients in South Korea and Thailand - Stock Titan
Pacira BioSciences, Inc. (PCRX) Stock Analysis: Exploring a 29.59% Potential Upside in Non-Opioid Pain Management Solutions - DirectorsTalk Interviews
Behavioral Patterns of PCRX and Institutional Flows - Stock Traders Daily
PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates - sharewise.com
Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt? - 富途牛牛
Pacira BioSciences (PCRX) Is Down 6.3% After Cut 2025 Outlook And Activist PressureHas The Bull Case Changed? - Sahm
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
2026-01-11 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Stockholders to Learn More About the Investigation | NDAQ:PCRX | Press Release - Stockhouse
Assessing Pacira BioSciences (PCRX) Valuation After Record EXPAREL Quarter Buybacks And Activist Pressure - Sahm
Pacira Stock (-9.6%): EXPAREL Decel Spooks the Street - Trefis
How Investors May Respond To Pacira BioSciences (PCRX) Activist Pressure Amid Buybacks And Rising EXPAREL Revenue - Yahoo Finance
Pacira BioSciences (NASDAQ:PCRX) Shares Gap DownHere's What Happened - MarketBeat
Is Pacira BioSciences Inc. (82P) stock supported by strong fundamentalsNew Releases Roundup & walk-ready comfort choices - ulpravda.ru
HC Wainwright Reaffirms Buy Rating for Pacira BioSciences (NASDAQ:PCRX) - MarketBeat
Pacira BioSciences' (PCRX) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
Pacira BioSciences (PCRX) Rating Reiterated as 'Buy' by HC Wainw - GuruFocus
What Analysts Are Saying About Pacira BioSciences Stock - Benzinga
Pacira BioSciences (PCRX) Receives 'Buy' Rating from Needham | P - GuruFocus
Pacira BioSciences Stock Pre-Market (-9.7%): Weak Preliminary 2025 Revenue - Trefis
Will Pacira BioSciences Inc. stock benefit from AI adoptionJuly 2025 Big Picture & Growth Focused Investment Plans - Улправда
Why Pacira BioSciences Inc. stock remains resilient2025 Big Picture & Detailed Earnings Play Strategies - Улправда
Signal Recap: Will Pacira BioSciences Inc. stock continue upward momentumJuly 2025 Catalysts & Short-Term High Return Ideas - Улправда
Pacira BioSciences (PCRX) Shares Dip After Revenue Outlook Cut - GuruFocus
Pacira (PCRX) Reports Strong 2025 Performance, Eyes Future Growt - GuruFocus
Pacira reports record EXPAREL sales with 7% volume growth in Q4 By Investing.com - Investing.com South Africa
Pacira reports record EXPAREL sales with 7% volume growth in Q4 - Investing.com
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues - The Manila Times
Tranche Update on Pacira BioSciences, Inc.'s Equity Buyback Plan announced on May 8, 2025. - MarketScreener
Is Pacira BioSciences Inc. stock dividend yield sustainableJuly 2025 Sector Moves & Free Reliable Trade Execution Plans - Улправда
Is Pacira BioSciences Inc. (82P) stock attractive post correctionShort Setup & Long-Term Growth Plans - ulpravda.ru
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Investors to Inquire about Securities Investigation - ACCESS Newswire
Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences - markets.businessinsider.com
Lauren Riker Sells 1,416 Shares of Pacira BioSciences (NASDAQ:PCRX) Stock - MarketBeat
Pacira Biosciences Inc Stock (PCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):